Ten years after the completion of the Human Genome Project, we stand on the cusp of an era of personalized medicine and the much hyped, sometimes maligned possibility of a "synthetic biology."
George Church, a leading figure in the human genome project, has long advocated the virtues of an "Open Source approach" (see Polonator.org the first open source sequencing machine). The Biobricks Foundation, and the newly created BioFab, work to create an open standard for the field of synthetic biology. Can an "Open Source" model, in which essential biotechnologies are accessible as an "innovation commons," provide a way forward? See Freeman Dyson for a vision of an era of radically "democratized," decentralized biology.
Drew Endy helped start the newest engineering major, Bioengineering, at both MIT and Stanford. His research teams pioneered the redesign of genomes and invented the transcriptor, a simple DNA element that allows living cells to implement Boolean logic. He is also a co-founder of Gen9, Inc., a DNA construction company, and the iGEM competition.
Thomas Goetz is a writer, entrepreneur and health care innovator. He is the author of the new book, The Remedy, which was chosen as a Best Book of the month by both iTunes and Amazon. His previous book, The Decision Tree: Taking Control of Your Health in the New Era of Personalized Medicine, was chosen by the Wall Street Journal as a Best Health book of 2010.
Thomas is also co-founder of Iodine, a health technology company with the mission of turning medical research data into clear and actionable tools for ordinary people to make better decisions about their health.
Tim Hubbard graduated with a BA in Biochemistry from University of Cambridge in 1985 and a PhD in Protein Design from the Department of Crystallography, Birkbeck College, London in 1988.
At the Sanger Institute Hubbard was a member of the strategy group that organized the sequencing of the human genome as part of the international public consortium. During this time he built up groups to analyze and annotate the sequences of vertebrate genomes. In 1999 he developed an automatic annotation system and starting applying it in real time to sequence output of the human genome project. This evolved into the Ensembl project with Michele Clamp and Ewan Birney from the European Bioinformatics Institute (EBI), which now provides annotation to more than 40 genomes. In parallel, the HAVANA group have carried out large scale manual annotation of human, mouse and zebrafish genomes.
Since 2007 Hubbard has been the principal investigator of GENCODE, a scale up programme of the ENCODE project, which brings together HAVANA, Ensembl and seven external groups to generate the reference geneset for the human genome. He is also the Sanger Institute principal investigator of the Genome Reference Consortium, which is responsible for reference genome sequences of human and mouse.
Alexander Wait Zaranek
Alexander Zaranek has been director of informatics at the Personal Genome Project since 2005. The PGP is the only project worldwide that provides "open-access" to well integrated human tissue-samples, genetic data and phenotype data. They were one of the first users of CC0. The commitment to openness has also led to his longtime collaboration on the Polonator which is the only open-innovation instrument platform for DNA sequencing. The Polonator, and related technologies, is part of the revolution that brought DNA sequencing costs down by 10,000-fold in the last four years. More recently it has also served as a platform for synthetic chemistry and cell biology in the same open device. Finally, along with his colleagues at the PGP, Zaranek has spearheaded an open clinical genome sequence interpretation and evidence database.
His professional interests include: personalized medicine, exascale computing, and free knowledge business models. When he can, he still enjoys tinkering with quantum lifeforms and synthetic biology.